Dihydroergocristine methanesulfonate

Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (Kd) of 25.7 nM and 9.8 μM, respectively[1].

Dihydroergocristine mesylate is the methanesulfonic acid salt of dihydroergocristine. It has been used as the for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. It is also a component of ergoloid mesylate (codergocrine mesilate), a mixture of ergot alkaloid derivatives that is used as a vasodilator and has shown mild benefits in the treatment of vascular dementia. It has a role as a vasodilator agent, an alpha-adrenergic antagonist and a geroprotector. It contains a dihydroergocristine.|A 9,10alpha-dihydro derivative of ERGOTAMINE that contains an isopropyl sidechain at the 2' position of the molecule.

4,10-Dihydroergocristine Methanesulfonate is an nontoxic and well tolerated drug that exerts agonistic and antagonistic activity on dopaminergic and adrenergic receptors. 4,10-Dihydroergocristine Methanesulfonate is known to exhibit protective properties to the brain against metabolic effects of ischemia by acting at a cellular level.

Molecular Weight:707.8
Hydrogen Bond Donor Count:4
Hydrogen Bond Acceptor Count:9
Rotatable Bond Count:5
Exact Mass:707.29888458
Monoisotopic Mass:707.29888458
Topological Polar Surface Area:181
Heavy Atom Count:50
Complexity:1300
Defined Atom Stereocenter Count:7
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes